




# OPEN TO ENROLLMENT

## Clinical Trial of Everolimus in Patients with *PTEN* Mutations



### WHO

- Individuals ages 5-45 with a *PTEN* Mutation who meet a series of safety inclusion criteria

### WHAT

- 6-month randomized controlled trial with everolimus
- Evaluate safety of everolimus and its potential to improve neurocognition

### HOW

- Developmental Testing
- Safety Blood Tests
- Eye-tracking
- Electrophysiological Measures

For more information please contact **Greg Geisel** at 617-919-1476 or [gregory.geisel@childrens.harvard.edu](mailto:gregory.geisel@childrens.harvard.edu)

The Developmental Synaptopathies Consortium (U54NS092090) is a part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS. This consortium is funded through a collaboration between the NCATS, the NINDS and the NIMH.

